Galectin research required to initiate clinical trials, subject to funding, will be based on internal development as opposed to a license as previously reported.

Boston, MA -- (ReleaseWire) -- 04/09/2020 -- BIOXYTRAN, INC. announced today that it intends to internally develop a novel carbohydrate Galactin inhibitor as opposed to licensing intellectual from Dr. David Platt as previously reported on March 24, 2020. The company's management believes that this approach will enable Bioxytran to develop a stronger intellectual property portfolio.

Dr. David Platt, Chief Executive Officer, remarked, "After reviewing the research and progress since the filing of my patent in 2009, I believe that we can be more responsive to the immediate needs posed by COVID-19 by developing a new patent portfolio rather than depending on my prior efforts. As a result, we terminated our prior licensing arrangement. Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis, including influenza and SARS providing a strong foundation to the hypothesis that Galectin-1 may be implicated in COVID-19.  Our new strategy should enable us to build on the new body of research to develop a stronger patent portfolio."

While Bioxytran will continue its plan to develop a pipeline of anti-necrosis drugs designed to treat hypoxia and our core strategy remains intact, the plan is to obtain additional funding for a proprietary Galactin-1 viral inhibitor developed internally and file for expedited trials under new FDA guidelines.

About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The Company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is designed to be 5,000 times smaller than red blood cells it is expected to penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in evaluation of the safety and efficacy of the BXT-25.

To learn more, visit the website: http://www.Bioxytraninc.com

Investor Relations
Resources Unlimited NW LLC
860.908.4133
info@resourcesunlimitedllc.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Company releases new COVID-19 slide deck on website.  

Boston, MA -- (ReleaseWire) -- 04/09/2020 -- BIOXYTRAN, INC., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the brain, heart, lungs, and other vital organs is announcing the launch of a new presentation detailing the expected mechanism of action between BXT-10 and COVID-19 in order to reduce the viral load.

Presentation Link:
https://uploads-ssl.webflow.com/5cd9cf5f4183373f6b248799/5e816a1a957e0adfc8334a8e_COVID-19%20Therapeutic%20%20%20V4.3%20%203_29_2020.pdf

Over the past decade there has been a strong body of evidence that indicates that Galectin-1 is implicated in viral pathogenesis.  The journal article titled Galectin-1 binds to influenza virus and ameliorates influenza virus pathogenesis demonstrates how viral pathogenesis is dependent upon galectin-1 in preclinical studies.  The article demonstrated the direct binding of galectin-1 to the influenza virus.  Yang et. al. indicated that "intranasal treatment of galectin-1 could enhance survival of mice against lethal challenge with influenza virus by reducing viral load, inflammation, and apoptosis in the lung."  This galectin-1 treatment resulted in a survival benefit of the mice and indicated theoretical mechanisms of action (MOA) in humans. 

The journal article titled Crystal Structure of Bovine Coronavirus Spike Protein Lectin Domain explored the evolution of the coronavirus N-terminal domains (NTDs) which are commonly referred to as coronavirus protein spikes. Guiguing Peng et. al. concluded that "Bovine coronavirus NTD shares structural folds and sugar-binding sites with human galectins and has subtle yet functionally important differences from protein-binding NTD of mouse coronavirus."  This study confirmed the linkage between the mouse coronavirus and humans.  There is much evidence to show that the coronavirus can jump between species.  Since this receptor is similar on both species there is a consensus among the Scientific advisory board that this will translate to efficacy in humans.     

The 2015 article titled, Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies demonstrated the similarities between influenza and SARS.  Dr Fang Li said "the following evolutionary scenario has been proposed for coronavirus S1-NTDs. Through gene capture, ancestral coronaviruses might have acquired a host galectin, which would become the S1-NTD of their spikes. Consequently, coronaviruses would recognize sugar receptors for cell entry."  Analysis of the crystalline structures showed the linkage between influenza and SARS.  COVID-19 is also known as SARS-CoV2 which is indicative that it is a subspecies of SARS.  The SARS virus has a "galectin fold" which in theory represents a binding spot on the virus for Bioxytran's galectin-1 inhibitor.

"The journal articles provide a strong foundation that galectin-1 is implicated in COVID-19," said CEO David Platt of Bioxytran Inc. and co-author of Galectin.  "It is clear in preclinical studies that galectin-1 was implicated in pathogenesis of the virus in mice.  Further study showed that the mice share the same N-terminal domain as humans.  There are also many similarities between SARS and COVID-19 because they share the similar N-terminal domain.   Based on these linkages the scientific team at Bioxytran formed its thesis that a galectin-1 inhibitor could bind to the coronavirus spikes and reduce viral load.  With the proper funding the company could be in human trials shortly."

About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The Company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in evaluation of the safety and efficacy of the BXT-25.

To learn more, visit the website: http://www.Bioxytraninc.com

Investor Relations
Resources Unlimited NW LLC
860.908.4133
info@resourcesunlimitedllc.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Journal Article correlates different neurological pathologies with Brain Metabolic Score and examines a neurological case study.

Boston, MA -- (ReleaseWire) -- 03/05/2020 -- BXT-25 a potential viable treatment for acquire deficiency syndrome associated with late-stage corona viral infected patients.

"BOSTON, MASSACHUSETTS, February 28, 2020 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the American Journal of Biomedical Science & Research released a peer-reviewed article that evaluated clinical situations in which the brain was resting or active using the Brain Metabolic Score's real-time multiparametric approach to data interpretation. (Mayevsky A. Real-Time Optical Monitoring of Brain Mitochondrial Function and Brain Metabolic Score (BMS) in Neuropathology. Am. J. Biomed. Sci.& Res. 7: 141- 172 (2020).)"

Animal studies were used to develop a mathematical model that essentially measures Brain Oxygen Balance. The article, entitled "Assessment of Brain Metabolic Score (MBS) In Vivo Based on Mitochondrial Activity in Neuropathology" was published by Prof. Avraham Mayevsky.

The article discusses the methodology used to prove that increased neuronal activity is correlated to the oxidation of NADH and that it can be measured using the Brain Metabolic Score. Additionally, this article serves as the rationale for using the Brain Metabolic Score as an endpoint in stroke and other neurodegenerative diseases where brain activity is compromised.

Other findings included in the animal experiments was that the monitoring of a very small sampling of the brain was representative of a volumetric sample of the brain that is able to detect global ischemia, anoxia, hypoxia, and hemorrhage. The device also demonstrated a minimally invasive way to measure cerebral ischemia which is essentially the supply of oxygen and carbon dioxide. Instead of disturbing and probing the brain tissue the probe was merely placed on the surface of the tissue.

The breakthrough came in what is described as "brain physiological mapping" that can use a minimally invasive technique to measure clinical conditions. These include Traumatic Brain Injury (TBI), brain ischemia, hemorrhage, hypothermia, sepsis, normobaric and hyperbaric oxygenation, and aging. In cases of brain activation, the device is capable of measuring different pathologies of cortical spreading depression, epileptic activity, and cerebral hypoxia.

A case study was presented whereby a patient with a head injury was taken to the ICU and connected to the Multiprobe Assembly (MPA) device. The patient responded to spontaneous changes to stimuli which matched all parameters, similar to the animal studies. The patient was monitored continuously for 7 hours and during that time was able detect a large increase in cerebral blood flow and the beneficial effect on brain oxygenation after treatment for high intracranial pressure 4.5 hours after being monitored to establish the patient's baseline.

Animal brains were tested in hyperbaric chambers that assessed the devices ability to detect increases or decreases in brain oxygenation. Tests also determined that the restoration of oxygen restored brain function. These tests were a proxy for using the Brain Metabolic Score as an endpoint to measure disease progression.

Neurodegenerative diseases are characterized by hypoxic tissue in the brain. There is clinical evidence that Hyperbaric Oxygen Therapy (HBOT) can reverse Alzheimer's Disease (AD). This disease indication represents a large unmet medical need. Researchers from Louisiana State University Health Sciences Center have the first PET scan-documented case of improvement in brain metabolism in AD in a patient that had hyperbaric oxygen chamber treatment.1 After 40 hyperbaric oxygen treatments over 66 days, the patient showed that they were able to halt the disease and temporarily reverse disease progression. These results are promising for the development of BXT-25, which in theory could provide a more extensive oxygen therapy for patients in a more convenient manner in the form of an intravenous shot.

"Determining biomarkers for neurodegenerative diseases has always been a challenge," said Dr. David Platt, CEO of Bioxytran Inc. "Subjective tests like the National Institute of Health Stroke Score (NIHSS) are used because no biomarkers exist to measure strokes. The Brain Metabolic Score has the potential to evolve into a biomarker that could be used to measure neurodegenerative diseases including Alzheimer's Disease. Advances in Alzheimer's has been stymied for years because the existing endpoints require thousands of patients to measure efficacy, which bloats the drug development costs and prolongs the studies. Powerful journal articles like this one, written by Myevsky, can sway the minds of key opinion leaders. When you take the work of Dr. Mayevsky and the work of the LSU Alzheimer study it really gives us a basis to pursue a clinical pathway in a field full of failures."

Platt continued "The linkage between hyperbaric oxygen treatment and BXT-25 is very strong. One can be substituted for the other. BXT-25 is an oxygen transport drug that was designed to be superior to hyperbaric oxygen treatment in many ways and not have all the constraints that currently exist for that treatment option. Both hyperbaric oxygen and BXT-25 are capable of treating the disease state of hypoxia in neurodegenerative diseases. Treating hypoxia in neurodegenerative diseases like Alzheimer's and stroke is a valid target that deserves further clinical investigation."

"I hope that my research paves the way for widespread use of the Brain Metabolic Score in clinical trials and eventually becomes an endpoint for various investigational drugs," said Avraham Mayevsky. "I also believe that patients in an ICU or a neurosurgical operation should be monitored for the Brain Metabolic Score. Surgeons in the operating room have to constantly filter data to determine the best course of treatment. If surgeons utilize the Brain Metabolic score they can quickly differentiate between localized and systemic issues during a surgical procedure allowing them to choose the optimal treatment pathway. There are many uses of the Brain Metabolic Score beyond surgery. As mentioned in my previous journal articles the Brain Metabolic Score could be easily adapted for use in testing different investigational drugs because the real-time monitoring would detect an increase in tissue oxygenation which is a consequence of the drug working to treat the desired indication."

"Key opinion leaders are warming up to the idea that hypoxia is a disease state that is treatable," said Juan Carlos Lopez-Talavera, Consulting Medical Director for Bioxtran Inc. "The latest Nobel Prize in health and medicine reinforced that many diseases have an element of hypoxia and appears to be more prevalent in neurodegenerative diseases. The Brain Metabolic Score is a true revolutionary concept in understanding brain functionality. It's important to see how one indicator can encapsulate so much functionality in a biomarker. BXT-25 is also an ideal molecule that is designed to deliver oxygen to starved organs including the brain. This is why Acute Respiratory Distress Syndrome (ARDS) is a good indication for BXT-25. The definition of ARDS is a lack of oxygenation in the blood that eventually leads to organ failure and death. ARDS is common after traumatic brain injury, sepsis, gastric aspiration, reperfusion injury, drug overdoses, cardiac surgery, pneumonia, inhalational injury, and respiratory infectious diseases including COVID-19."

About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain. Hypoxic brain injuries such as ischemic strokes could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs, the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in evaluation of the safety and efficacy of the BXT-25. To learn more, visit our website: http://www.Bioxytraninc.com.

References:
Hyperbaric oxygen therapy for Alzheimer's disease (January 24, 2019) Retrieved from https://www.sciencedaily.com/releases/2019/01/190124124742.htm

Contact:
Bioxytran
David.platt@bioxytraninc.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Boston, MA -- (ReleaseWire) -- 02/28/2020 -- BIOXYTRAN, INC., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the brain, heart, lungs, and other vital organs is announcing its intention to explore partnering with international drug companies looking to treat end-stage Wuhan Coronavirus patients that have Acute Respiratory Distress Syndrome (ARDS).  A majority of late-stage coronavirus patients that end up with acute respiratory distress syndrome (ARDS) which has been commonly referred to as Severe Respiratory Distress Syndrome (SRDS) during this latest outbreak. 

Until a vaccine is developed traditional methods of containment and prevention are the primary weapons of controlling the disease.  According to the Centers for Disease Control (CDC) there are no known treatments for the 2019 Novel Coronavirus and this represents a growing unmet medical need.  The primary cause of death from respiratory viruses like the coronavirus and influenza are the result of the fluids accumulating inside the tiny air sacs of the lungs which ultimately leads to a breakdown of the surfactant lining in the air sacs guiding the transfer of oxygen to the blood. Acute Respiratory Distress Syndrome (ARDS) is a progressive disease characterized by low blood oxygen levels due to the buildup of fluids.  The only treatment for ARDS is oxygen therapy along with ventilator support.  In addition, diuretics are used to help increase urination in order to manage the fluid levels to prevent a buildup of fluid in the lungs. In extreme cases, extracorporeal membrane oxygenation (ECMO), which takes blood out of your body and removes carbon dioxide and returns oxygen to the body could be used.  

Bioxytrans lead drug candidate BXT-25 is designed to be 5000 times smaller than blood cells and transport oxygen throughout the body.  The half-life of BXT-25 is 9 hours and will continuously circulate until it's processed by the liver. During this time it will receive oxygen from the lungs and deliver it to organs and tissues throughout the body that need it.  In the case of ARDS, the diffusion of oxygen to the blood in the alveoli is compromised, but the small size of BXT-25 should allow it to get closer to the oxygen in the lungs. These oxygen carriers flow freely throughout the body, especially to the vital organs.  As long as these organs continue to receive oxygen, the patient can survive.  This therapy should provide the patient with enough time to recover.  Eventually, the body's own immune system will kill the virus and enable the patient to enjoy a full recovery. 

"This could be a major advancement in the treatment of end-stage patients infected with the Wuhan Coronavirus," said CEO David Platt of Bioxytran Inc.  "In situations like this pandemic, where resources are stretched to their limits, we are looking to develop a common-sense solution to improve the mortality rate of this disease right away.  Vaccines could be the answer, but they take time.  We believe that potential partners will recognize that we have an immediate solution to treat acute patients with BXT-25.  Even if an acute patient beats the disease down to a zero viral load they could still die from the ARDS.  To fight the disease on another front, we also have the opportunity to upgrade the MDX Viewer to enable remote monitoring.  The FDA approved the MDX Viewer to measure the tissue metabolic score, which is capable of predicting organ failure.  Having a diagnostic that measures the oxygen consumption of the organs not only helps triage patients, but it also enables researchers to conduct clinical trials in real-time by measuring the oxygen consumption in the organs after the drug was taken.  The primary reason the coronavirus is so lethal is because the body fails to deliver oxygen.  This is such a fundamental concept that we feel confident that we will be successful partnering for the ARDS due to the Wuhan Coronavirus indication."       

"BXT-25 represents a way to deliver oxygen to tissue without the intervention of the alveoli," said Dr. Juan Carlos Lopez-Talavera, Bioxtyran's Medical Advisor.  "The only treatment for ARDS patients is a ventilator and in extreme situations extracorporeal membrane oxygenation (ECMO), which takes blood out of your body and removes carbon dioxide and returns oxygen to the body.  In ARDS patients, we believe the molecule will diffuse into and out of the fluid in the alveoli in order to achieve oxygenation of the molecule.  Reports from the CDC have indicated that the mortality rate is disproportionately higher for the elderly or those with underlying medical conditions.  In ARDS alone the mortality rate is 60% in individuals over age 85.  BXT-25 is not expected to have any side effects." 

About MDX Life Sciences Inc.
MDX Life Sciences, Inc. is a clinical-stage biotechnology company developing autologous transplantation techniques for tissue and organ regeneration.  The focus of the development programs is on Myocardial Ischemia, reperfusion injury, Epilepsy, Traumatic Brain Injury, and neurodegenerative and neuromuscular diseases.  These diseases include Huntington's disease, Multiple Sclerosis/Optic Neuritis, Wolfram Syndrome, Epilepsy, Traumatic Brain Injury (TBI), Duchenne Muscular Dystrophy (DMD), Alzheimer's disease, and Parkinson's disease.  Continuing research has linked these diseases to various malfunctions of the mitochondria.  Mitochondrial transplantation is a procedure that can open up the possibilities of disease-modifying treatments resulting in tissue regeneration which would be a clear clinical endpoint for almost all these diseases.  Using the TMS calculated by the MDX Viewer will open up a new era in monitoring of patients during operations as well as in the Intensive Care Units.  For additional info on our MDX Lifesciences, please visit www.mdxlifesciences.com

About 2019 Novel Coronavirus
The 2019 Novel Coronavirus (2019-nCoV) was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of 2019-nCoV is uncertain and it is unclear how easily the virus spreads. 2019-nCov is thought to be transmitted person to person through respiratory droplets, commonly resulting from coughing sneezing and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed 2019-nCoV infections, symptoms have included fever, cough, and shortness of breath.  It is believed that symptoms of 2019-nCoV may appear in as few as two days or as long as 14 days prior to exposure, and that symptoms in patients have ranged from non-existent to severe and fatal. There are currently no known anti-viral treatments effective at suppressing 2019-nCoV.

About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs, the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in the evaluation of the safety and efficacy of the BXT-25.  To learn more, visit our website: http://www.Bioxytraninc.com

CONTACT:
David Platt
david.platt@bioxytraninc.com
617-510-2539

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

MDX Viewer use during open heart surgery is an essential vital sign that could mitigate the risk of brain damage caused by prolonged oxygen deprivation during perioperative cardiovascular procedures and validates tissue oxygenation in the brain for stoke patients.

Boston, MA -- (ReleaseWire) -- 06/21/2019 -- BIOXYTRAN, INC. a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the American Journal of Cardiovascular and Thoracic Surgery published a peer reviewed article that validated animal models that showed the correlation between the surgical procedure and a new vital sign called the Tissue Metabolic Score (TMS).  A group of patients were monitored during a typical aortic occlusion surgery as well as during coronary arteries bypass procedures. The article, entitled "Perioperative Cardiovascular Evaluation of Patients Oxygen Balance and Tissue Metabolic Score (TMS)" was published by Prof. Avraham Mayevsky. The FDA approved monitoring device -CritiView- was renamed by MDX Life Sciences to the MDX Viewer.  Bioxytran has an exclusive licensing agreement with MDX Life Sciences to measure cellular health and believes that expansion into cardiovascular surgeries is warranted. 

The article distinguished that patients undergoing perioperative cardiovascular surgeries (open heart surgery) are at greater risk of brain damage and that early warning tools like the MDX Viewer can minimize the effect of surgeries during the perioperative stage.  The TMS essentially gives the surgeon immediate feedback on tissue oxygenation and allows the surgeon to take corrective action if necessary to protect the brain during surgery and the post-operative period. The article covers the animal studies and the results the ultimately led to the evaluation of 11 patients during open heart surgery.  The device measures 4 parameters and uses an algorithm to calculate the Tissue Metabolic Score. The primary measure is the Nicotineamide Adenine Dinucleotide (NADH) redox state.  NADH is a coenzyme in part of the respiratory chain in the mitochondria responsible for the Krebs cycle which oxidizes carbohydrates and fats and turns it in cell energy known as adenosine triphosphate (ATP).  NADH absorbs light at 320-380 nm and emits fluorescent light at 420-480 nm range.  The MDX Viewer measures the changes in fluorescence and reflectance and is part of the calculation of the TMS.  In addition, the instrumentation measures the levels of oxygenated hemoglobin and the Doppler shift in the microcirculation which is factored into the TMS.  Bixoytran expects to use an updated form of the MDX viewer during phase 2 clinical trials and believes that it will be accepted as a surrogate marker in stroke patients.    
   
"This study just serves to reinforce the medical need to measure tissue oxygenation levels during surgical procedures" said Dr David Platt, CEO of Bioxytran.  "It also underscores how essential BXT-25 could be to any surgical procedure because it can be used before, during, and after treatment without any harmful side effects.  The data from this pilot study is small yet compelling because it demonstrates how surgeons can greatly reduce the risk of brain damage through careful monitoring of the TMS. It is our hope that this publication brings more awareness to the topic because according to the Journal of the American College of Cardiology (JACC) post-operative cognitive dysfunction (POCD) may be detected in 14 – 48% of patients.  This is a staggering statistic when taking into account that 500,000 Coronary Artery Bypass Grafting (CABG) surgeries are performed annually.  These findings continue to strengthen the argument that BXT-25 is a platform technology with an enormous impact.  This article could serve as the scientific basis of a licensing agreement with a medical device maker."
 
"Post-operative cognitive dysfunction (POCD) is not a new issue and has been with us since open heart surgeries were perfected in the mid 80's" said Juan Carlos Lopez-Talavera, MD, PhD.  "Until now, all we have been able to do is measure and record the incidence of the brain damage after surgery.  Faster surgeries could lower the incidence of POCD, but now we have a predictive real time vital sign that tells us to take corrective action during the surgery.  For over 30 years there has been very little advancement in this field of study and we believe that this could be a paradigm shift in the way we perform and treat open heart surgeries." 

"The MDX Viewer is a very versatile machine" said Avraham Mayevsky.  "The TMS is a real time predictive value that surgeons can easily decipher with respect to the oxygen balance in the brain.  Based on the feedback during surgery, the TMS can give surgeons more of an opportunity to take corrective action and thereby lower the incidence of potential brain damage.  The operating room (OR) is an ideal place for the MDX viewer and open heart surgery represents one of the many potential uses.  We think there is an excellent medical argument that the MDX viewer should be part of the standard of care in open heart surgery and eventually adopted as a permanent fixture in the OR room.        

About MDX Life Sciences Inc.
MDX Life Sciences, Inc. is a clinical stage biotechnology company developing autologous transplantation techniques for tissue and organ regeneration.  The focus of the development programs is on Myocardial Ischemia, reperfusion injury, Epilepsy, Traumatic Brain Injury and neurodegenerative and neuromuscular diseases.  These diseases include Huntingtons's Disease, Multiple Sclerosis/Optic Neuritis, Wolfram Syndrome, Epilepsy, Traumatic Brain Injury (TBI), Duchenne Muscular Dystrophy (DMD), Alzheimer's Disease, and Parkinson's Disease.  Continuing research has linked these diseases to various malfunctions of the mitochondria.  Mitochondrial transplantation is a procedure that can open up the possibilities of disease modifying treatments resulting in tissue regeneration which would be a clear clinical endpoint for almost all these diseases.  Using the TMS calculated by the MDX Viewer will open up a new era in monitoring of patients during operations as well as in the Intensive Care Units.  For additional info on our MDX Lifesciences, please visit www.mdxlifesciences.com.

About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in evaluation of the safety and efficacy of the BXT-25. 

To learn more, visit http://www.Bioxytraninc.com

Investor Relations
Resources Unlimited NW LLC
860.908.4133?
info@resourcesunlimitedllc.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Future use of the MDX Viewer likely to start in operating rooms, clinical trials to measure tissue balance in stroke, and to test the viability of an organ before transplantation.

Boston, MA -- (ReleaseWire) -- 06/18/2019 -- BIOXYTRAN, INC. a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Journal of Emergency Medicine and Care published a peer-reviewed article that describes a revolutionary new vital sign called the Tissue Metabolic Score (TMS). The monitoring device measures mitochondrial function and microcirculation hemodynamics that are integrated and displays the TMS and plots it versus time. The article, entitled "Oxygen Balance Homeostasis and Tissue Metabolic Score (TMS) of Patients In Emergency and Critical Care Medicine" was published by Prof. Avraham Mayevsky in Volume 1, Issue 2 in the Journal of Emergency Medicine and Care. The FDA approved monitoring device -CritiView- was renamed by MDX Life Sciences to the MDX Viewer. Bioxytran has an exclusive licensing agreement with MDX Life Sciences to measure cellular health.

The premise of the article is that patients that are admitted to the operation rooms or intensive care units (ICUs) need real-time monitoring of a new vital sign called TMS. Monitoring the TMS allows clinicians and surgeons an early warning sign into the health of most vital organs like the heart and brain. The article covers the evolution of the monitoring device and the inner workings of the MDX viewer. The device measures 4 parameters and uses an algorithm to calculate the Tissue Metabolic Score. The primary concept that underpins the technology is Oxygen Balance Homeostasis that dates back to 1914. The principal of Oxygen Balance Homeostasis is that organs are unable to increase their activity without a corresponding increase in oxygen consumption delivered by increased blood flow. Monitoring the TMS in certain less vital organs serves a proxy of tissue health in the most vital organs. The MDX viewer uses a minimally invasive multiparametric monitoring device connected to the patient's urethral wall via a 3-way Foley catheter to measure TMS. When vital organs in the body are stressed, blood flow is diverted from less vital organs to the most vital organs and the TMS will fall. These changes can be measured with the MDX viewer to track tissue oxygenation levels in vital organs. A key case study done in cardiovascular operated patients underwent bypass of the coronary arteries procedure. During this type of operation, the TMS of the Urethral wall decreased significantly and then recovered toward the end of the operation as expected.

"Measuring the level of tissue oxygenation in diseases and surgical procedures could have a profound effect in clinical research," said Dr. David Platt, CEO of Bioxytran. "In the past, researchers trying to prove the efficacy of a procedure on a vital organ like the brain had to rely on surrogate markers such as cognitive tests which require large patient populations and relatively subjective tests. With the advent of the FDA approved MDX Viewer, researchers can now accelerate their studies using the TMS biomarker and likely save a lot of money in the process. Tissue oxygenation levels are also important in tissue regeneration, stem cell transplantation, tissue transplantation, and tissue viability. The licensing opportunities in this area are boundless. Bioxytran's initial focus will be for patients of a stroke, Acute Respiratory Deficiency Syndrome (ARDS), sepsis, and heart failure. The stroke market is estimated at 900,000 annually. Since there is an unmet medical need in the stroke indication, Bioxytran will be primarily focusing its efforts in advancing BXT-25 through the clinical trials."

About MDX Life Sciences Inc.
MDX Life Sciences, Inc. is a clinical stage biotechnology company developing autologous transplantation techniques for tissue and organ regeneration. The focus of the development programs is on Myocardial Ischemia, reperfusion injury, Epilepsy, Traumatic Brain Injury, and neurodegenerative and neuromuscular diseases. These diseases include Huntington's Disease, Multiple Sclerosis/Optic Neuritis, Wolfram Syndrome, Epilepsy, Traumatic Brain Injury (TBI), Duchenne Muscular Dystrophy (DMD), Alzheimer's Disease, and Parkinson Disease. Continuing research has linked these diseases to various malfunctions of the mitochondria. Mitochondrial transplantation is a procedure that can open up the possibilities of disease-modifying treatments resulting in tissue regeneration which would be a clear clinical endpoint for almost all these diseases. Using the Total Metabolic Score (TMS) calculated by the MDX Viewer will open up a new era in the monitoring of patients during operations as well as in the Intensive Care Units. For additional info on our MDX Lifesciences, please visit www.mdxlifesciences.com

About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain. Hypoxic brain injuries such as ischemic strokes could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs, the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in evaluation of the safety and efficacy of the BXT-25. To learn more, visit our website: http://www.Bioxytraninc.com

Investor Relations
Resources Unlimited NW LLC
860.908.4133
info@resourcesunlimitedllc.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Future use of the MDX Viewer likely to start in operating rooms, clinical trials to measure tissue balance in stroke, and to test the viability of an organ before transplantation.

Boston, MA -- (ReleaseWire) -- 05/22/2019 -- BIOXYTRAN, INC., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Journal of Emergency Medicine and Care published a peer-reviewed article that describes a revolutionary new vital sign called the Tissue Metabolic Score (TMS).  The monitoring device measures mitochondrial function and microcirculation hemodynamics that are integrated and displays the TMS and plots it versus time.  The article, entitled "Oxygen Balance Homeostasis and Tissue Metabolic Score (TMS) of Patients In Emergency and Critical Care Medicine" was published by Prof. Avraham Mayevsky in Volume 1, Issue 2 in the Journal of Emergency Medicine and Care.  The FDA approved monitoring device -CritiView- was renamed by MDX Life Sciences to the MDX Viewer. Bioxytran has an exclusive licensing agreement with MDX Life Sciences to measure cellular health. 

The premise of the article is that patients that are admitted to the operation rooms or intensive care units (ICUs) need real-time monitoring of a new vital sign called TMS. Monitoring the TMS allows clinicians and surgeons an early warning sign into the health of most vital organs like the heart and brain.  The article covers the evolution of the monitoring device and the inner workings of the MDX viewer.  The device measures 4 parameters and uses an algorithm to calculate the Tissue Metabolic Score.  The primary concept that underpins the technology is Oxygen Balance Homeostasis that dates back to 1914.  The principal of Oxygen Balance Homeostasis is that organs are unable to increase their activity without a corresponding increase in oxygen consumption delivered by increased blood flow.  Monitoring the TMS in certain less vital organs serves a proxy of tissue health in the most vital organs.  The MDX viewer uses a minimally invasive multiparametric monitoring device connected to the patient's urethral wall via a 3-way Foley catheter to measure TMS.  When vital organs in the body are stressed, blood flow is diverted from less vital organs to the most vital organs and the TMS will fall.  These changes can be measured with the MDX viewer to track tissue oxygenation levels in vital organs.  A key case study done in cardiovascular operated patients underwent bypass of the coronary arteries procedure.  During this type of operation, the TMS of the Urethral wall decreased significantly and then recovered toward the end of the operation as expected.   

"Measuring the level of tissue oxygenation in diseases and surgical procedures could have a profound effect in clinical research," said Dr. David Platt, CEO of Bioxytran.  "In the past, researchers trying to prove the efficacy of a procedure on a vital organ like the brain had to rely on surrogate markers such as cognitive tests which require large patient populations and relatively subjective tests.  With the advent of the FDA approved MDX Viewer, researchers can now accelerate their studies using the TMS biomarker and likely save a lot of money in the process.  Tissue oxygenation levels are also important in tissue regeneration, stem cell transplantation, tissue transplantation, and tissue viability.  The licensing opportunities in this area are boundless. Bioxytran's initial focus will be for patients of a stroke, Acute Respiratory Deficiency Syndrome (ARDS), sepsis, and heart failure.  The stroke market is estimated at 900,000 annually.  Since there is an unmet medical need in the stroke indication, Bioxytran will be primarily focusing its efforts in advancing BXT-25 through the clinical trials." 

About MDX Life Sciences Inc.
MDX Life Sciences, Inc. is a clinical stage biotechnology company developing autologous transplantation techniques for tissue and organ regeneration.  The focus of the development programs is on Myocardial Ischemia, reperfusion injury, Epilepsy, Traumatic Brain Injury, and neurodegenerative and neuromuscular diseases.  These diseases include Huntington's Disease, Multiple Sclerosis/Optic Neuritis, Wolfram Syndrome, Epilepsy, Traumatic Brain Injury (TBI), Duchenne Muscular Dystrophy (DMD), Alzheimer's Disease, and Parkinson Disease. Continuing research has linked these diseases to various malfunctions of the mitochondria.  Mitochondrial transplantation is a procedure that can open up the possibilities of disease-modifying treatments resulting in tissue regeneration which would be a clear clinical endpoint for almost all these diseases.  Using the Total Metabolic Score (TMS) calculated by the MDX Viewer will open up a new era in the monitoring of patients during operations as well as in the Intensive Care Units.  For additional info on our MDX Lifesciences, please visit www.mdxlifesciences.com.

About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs, the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in the evaluation of the safety and efficacy of the BXT-25.  To learn more, visit the website: http://www.Bioxytraninc.com.

Investor Relations
Resources Unlimited NW LLC
860.908.4133
info@resourcesunlimitedllc.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Boston, MA -- (ReleaseWire) -- 05/21/2019 -- BIOXYTRAN, INC., a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that it has retained Juan Carlos Lopez-Talavera, MD, PhD to join Bioxytran's Scientific Advisory Board to manage the company's FDA regulatory application process for Bioxytran's flagship drug, BXT-25.

"Dr.  Lopez-Talavera will play an important role in overseeing our new drug through the FDA's regulatory process," stated Bioxytran CEO, David Platt. "Juan has been instrumental in expediting well-known drugs such as OCALIVA® through the regulatory process.  We believe that Juan's personal and professional relationships with some of the top pharmaceutical companies and Key Opinion Leaders will bring great value to Bioxytran. His experience in tissue regeneration will bring great skills to our FDA application process and designing our trials for Ischemic Stroke. Bioxytran is truly fortunate to acquire talent of such a high caliber."

"Dr. Lopez-Talavera has a reputation of developing disruptive technologies which we believe is critical for compounds such as Bioxytran's BXT-25. It is rare to obtain such a qualified candidate in a developmental stage company like Bioxytran, and we view it as an endorsement of our plans for BXT-25."

Dr. Lopez-Talavera has over 20 years of experience in the biopharma industry, with extensive expertise in liver and gastrointestinal diseases. Most recently, Dr. Lopez-Talavera was Senior Vice President, Head of Medical Affairs and member of the Executive Team at Intercept Pharmaceuticals. Previously he held positions at AbbVie as Head of Medical Affairs, Global Research and Development, Bristol Myers Squibb, as Vice President and Global Development Lead, and Roche Laboratories as Senior Medical Director. Before moving into the industry, Dr. Lopez-Talavera was an Assistant Professor with the Divisions of Gastroenterology and Hepatology, and Endocrinology and Pathology at the University of Pittsburgh Medical Center, Associate Professor of Medicine with the Universidad Autonoma de Barcelona and Attending Physician of the Liver Unit at the Hospital General Universitari Vall D'Hebron in Barcelona.

"In my professional career I have always gravitated toward working with novel mechanisms. " said Dr. Lopez-Talavera.  "The opportunity at Bioxytran is so vast, because tissue oxygenation represents a true unmet medical need and represents a tremendous untapped opportunity to target both the Ischemic Stroke and, has future potential for Acute Respiratory Distress Syndrome ("ARDS"). BXT-25 has the unique ability to deliver oxygen through a small molecule which can be effective in extending the "golden hour" in stroke victims and potentially for tissue regeneration in ARDS victims. I am honored to be part of this team and look forward to advancing the science and creating partnerships or joint ventures that will grow this field of research."  

Dr. Lopez-Talavera was a Postdoctoral Fellow at the Yale University School of Medicine, and Clinical Observer at Sloan Kettering Memorial Cancer Center. He holds an M.D. and a Ph.D. in Hepatology from the Universidad Autonoma de Barcelona.

About Bioxytran, Inc.
Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain.  Hypoxic brain injuries such as ischemic strokes could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs, the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. To learn more, visit our website: http://www.Bioxytraninc.com.

Investor Relations
Resources Unlimited NW LLC
860.908.4133
info@resourcesunlimitedllc.com

Forward-Looking Statements

This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions, and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm